Clinical Trial Update: Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Trastuzumab Rezetecan with Trastuzumab Deruxtecan as neoadjuvant therapy for HER2-positive breast cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab Rezetecan
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING